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Abstract
Background: Public policy and clinical treatment in tobacco addiction in the UK has focused on cessation: an
abrupt attempt to stop all cigarettes. However, recent evidence suggests that allowing more gradual withdrawal
from tobacco or even permanent partial substitution by nicotine replacement therapy (NRT) could lead to net
benefits to public health. No jurisdiction has introduced smoking reduction programmes in normal clinical care
and the best methods for their implementation is uncertain. Community pharmacists offering smoking cessation
services in the UK are ideally placed to implement reduction programmes.
This pilot study aims therefore to examine the feasibility of implementing smoking reduction programme in
pharmacies, and also to see if behavioural support and a longer treatment affect the success rate for cessation.
Design and methods: This is a 2 × 2 randomised factorial trial of behavioural support versus no support and short
versus standard length reduction programme. The pharmacists will recruit 16 patients per pharmacy, 160 smokers
altogether. Pharmacists will randomise each participant by sealed envelopes. In a standard supported programme, the
pharmacist will give support for 34 weeks, inviting participants to set a treatment goal and providing advice on how to
reduce cigarette use. Participants in the short programme will be given the same advice on how to reduce but will
reduce smoking over four weeks. Participants in the no support arms will be given a leaflet that describes the reduction
programmes in 4-week and 34-week format. All participants are encouraged to use of NRT to support the reduction.
These processes will be measured by recording the number of recruited smokers; percentage of those who reduce and
sustain their consumption to at least 50% of baseline value, and the proportion of people who attain 4 weeks abstinence
and 6 months abstinence. Interviews will assess smokers’ and pharmacists’ views on the way the programme ran.
Discussion: This is a pilot study to assess the feasibility of offering smoking reduction programme within
pharmacies that offer naturalistic setting to show population benefit from these programmes. Findings from this
trial will inform the development of evidence-based treatment for smokers who want to reduce and best
approaches to engage reluctant quitters onto the programme.
Trial Registration: Current Controlled Trials ISRCTN 2010-019259-24
Keywords: Smoking, Tobacco Dependence, Controlled Clinical Trials, Randomized, Pharmacists, Harm Reduction
Background
Clinical treatment in tobacco addiction has almost
exclusively focused on cessation - an abrupt attempt to
stop smoking. Some smokers, however, feel that cutting
down is an appropriate way to stop smoking. In the
English Smoking Toolkit study, 57% of current smokers
reported they were cutting down, of whom 26% were
using nicotine replacement therapy (NRT) to assist this
[1,2]. The UK Department of Health (DH) new tobacco
control strategy proposes supporting smokers who feel
unable to quit to reduce smoking as a precursor to quit-
ting. No jurisdiction, however, has introduced reduction
programmes in normal clinical care.
The evidence that smoking reduction might benefit
public health is derived from clinical trials, surveys, and
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review of RCTs and health economic analysis [2,3]
found that smoking reduction programmes doubled
long-term abstinence rates, with absolute effectiveness
only slightly lower than comparable cessation pro-
g r a m m e s .T h ec o s tp e rq u a l i t ya d j u s t e dl i f ey e a rw a s
less than £2000 for most age groups, rising to less than
£5000/QALY for the oldest.
The US guidance, however, recently concluded there
was insufficient evidence to recommend smoking reduc-
tion programmes [4]. The main concern is that offering
reduction alongside cessation programmes will divert
smokers from more effective and cheaper cessation pro-
grammes to ‘easier’ but less effective and more expensive
reduction programmes. Second, trials of smoking reduc-
tion offered free support and medication in countries
where such help for smoking cessation is neither widely
available nor free and so trials may have inadvertently
enrolled smokers keen on cessation rather than reduction
and that would have caused the increase in cessation seen
in the intervention groups. Third, the trials took place in
specialist clinics and drew in highly motivated participants.
Consequently the best methods for implementation of
reduction programmes outside of such contexts are uncer-
tain and this need to be testedin naturalistic settings to
show population benefit from these programmes.
As recognised in Action on Smoking and Health (ASH)
guidance to the NHS [5], specialist stop smoking services
in the UK do not have the resources necessary to imple-
ment smoking reduction programmes. NHS stop smoking
service practitioners treat approximately only 30% of all
smokers. If the nicotine assisted smoking reduction pro-
grammes were to fulfill their potential, up to 5 million
smokers might be helped by them. Specialist stop smoking
services, however, would not have the workforce to over-
see such large numbers of smokers. Therefore the wider
primary care workforce might need to help implement
reduction programmes.
Community pharmacists are ideally placed to implement
reduction programmes. They already provide smoking ces-
sation services as part of the NHS stop smoking service,
treating 16% of smokers helped by the NHS in 2008/9.
They recruit patients to the service primarily by providing
opportunistic brief advice to smokers and therefore they
offer a naturalistic setting to test whether reduction pro-
grammes can be implemented alongside cessation
programmes.
There are no trials investigating whether behavioural
support enhances the success of reduction programmes.
There are, however, such trials for cessation programmes,
which show that behavioural support increases by
50-100% the efficacy of abrupt cessation programmes
[6,7]. Industry-sponsored trials of NRT versus placebo
provided regular behavioural support and monitoring
lasting 15-30 minutes per visit over nine visits [2,3].
Therefore, it is reasonable to believe that reduction pro-
grammes work with support, but it is unclear whether
support enhances efficacy or whether it is necessary. One
study examined the efficacy of NRT versus placebo in
smokers that wanted to quit slowly by reduction [8].
Trial participants received no behavioural support. This
trial showed a near trebling of long-term abstinence with
NRT relative to placebo (OR = 2.86, 95%CI 1.93 to 2.94).
These data suggest support might not be necessary.
However, although no behavioural support was offered,
this study included three visits to assess reduction and
cessation, which might motivate adherence to the pro-
gramme, and hence this might not be a true study of
effectiveness of medication without behavioural support.
Determining the optimum level of support and monitor-
ing necessary for efficacy in reduction programmes is a
priority for NHS implementation.
One NRT industry sponsored trial enrolled partici-
pants who did not intend to stop smoking in the next
month and randomised them to reduce over one month
then stop or to reduce then stop over the typical 6-9
months adopted in the UK [9]. Despite the lack of intui-
tive fit between participants’ intentions and the short
programme, the four week reduction programme was
more effective than the nine month programme assessed
12 months from the start. For confirmed prolonged
reduction, the Mantel-Haenszel relative risk (RR) (95%
CI) was 2.69 (1.08-6.68) and for confirmed prolonged
abstinence it was 4.57 (1.00-20.93). Shorter and more
manageable reduction programmes may be more effec-
tive than the standard six-month programme.
We propose to assess by using mixed method approach
whether pharmacists can be trained to implement a nico-
tine assisted reduction programme, how well they do so,
and how this is received by smokers and by pharmacists.
We also aim to test whether behavioural support adds to
the effectiveness of reduction programmes and whether
short or standard length programmes are more effective.
Aims and objectives
Aim
To examine the feasibility of introducing nicotine
assisted reduction to stop in pharmacies.
To estimate the efficacy of:
￿ more rapid versus slower reduction programmes
￿ behavioural support relative to self-help support
only.
Objectives
Primary objectives
1) To examine whether pharmacists can be trained to
engage smokers who do not want to quit and enrol
them in a smoking reduction programme.
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Page 2 of 132) To compare the relative efficacy of short versus
standard length reduction programmes on smoking
reduction and smoking cessation.
3) To examine the relative efficacy of supported versus
self-guided reduction programmes on smoking reduc-
tion and smoking cessation.
Secondary objectives
1) To assess which strategies used in enrolment and
implementation of the programmes were successful and
unsuccessful.
2) To estimate the proportion of smokers enrolled in
reduction programmes who reduce successfully.
3) To estimate the proportion of smokers who are
referred to cessation programmes and quit successfully.
4) To obtain trial participants’ and pharmacists’ views
on the value of reduction programmes and how such
programmes might be improved in future.
Methods/Design
Participant Recruitment
Pharmacists who work for NHS stop smoking services will
be recruited from areas of high smoking prevalence in Bir-
mingham and Yorkshire region; those treating at least four
new smokers for cessation per month will be eligible. Over
60 pharmacists in Birmingham see this many patients in
the NHS stop smoking service and most are recruited by
brief interventions across the counter, thus providing a
naturalistic setting in which to test the implementation of
reduction programmes and integration with other smok-
ing cessation efforts.
We plan to recruit 10 pharmacies and for each to recruit
four participants into a reduction programme each month,
providing a quota of 16 in four months. We plan two
waves of recruitment. Using two waves will allow us to
learn lessons from the first wave, which is consistent with
the developmental nature of this trial.
Educational outreach visits are effective in changing
GP’s behaviour [10]. We will make visits to local GPs to
inform them about the programme and encourage them
to refer reluctant quitters to the reduction programme.
GPs will be given referral cards for their local pharmacy
provider to give to patients. If the recruitment of partici-
pants is particularly slow during the either wave, GP’s will
be asked to send a letter to their registered current smo-
kers. The letter will inform them that the reduction pro-
gramme is available at their local pharmacy. It will also
give details of how they can take part, should they want to,
along with an information leaflet about the study.
Pharmacists will be asked to recruit participants oppor-
tunistically as well as receiving referrals from GPs. To
assist opportunistic recruitment, pharmacists will display
a poster in the window. Pharmacists will be compensated
for their time with service support funding.
Training for professionals
Pharmacists will be trained in two evening sessions;
attendance to both training sessions is required. In the
first session, presentations will be given on principles of
the reduction programmes and practicalities of running
the trial from recruitment to the final behavioural sup-
port visit. The second training session will give pharma-
cists the opportunity to practice what was learned in the
first session by role plays. The pharmacists will be reim-
bursed for their time of attending to the training. The
research team will keep in regular contact with the phar-
macy staff and help deal with problems arising during the
trial.
Inclusion criteria
Participants must meet all of the following inclusion
criteria:
1) aged 18 years or older.
2) daily smokers with either a CO of at least 10 parts
per million (ppm) at least 15 minutes after last smoking
or smoke at least 10 cigarettes or 8 g of loose tobacco
as “roll up” cigarettes daily.
3) do not intend to stop in the next month, but are
prepared to reduce their consumption with any of the
programmes offered.
4) evidence of a personally signed and dated informed
c o n s e n td o c u m e n ti n d i c a t i n g that the participant has
been informed of all pertinent aspects of the study and
consents to participate and be randomised to either arm.
5) have either a telephone or email for follow-up.
Exclusion criteria
There are no contraindications for smokers using NRT.
However, there are situations where caution is required.
This trial will be conducted with minimal clinical moni-
toring using treatment regimens that have not been pro-
ven to have a population benefit and therefore we have
elected to exclude potential participants who have cau-
tions for NRT and this represents the bulk of exclusion
criteria. Participants presenting any of the following
exclusion criteria will be excluded:
1. currently using other NRT, bupropion, nortriptyline,
mecamylamine, reserpine, or varenicline, or undergoing
any treatment for tobacco dependence (e.g. acupunc-
ture) that they are not willing to stop using.
2. unstable angina pectoris, myocardial infarction,
acute coronary syndrome, or cerebrovascular accident
during the last 3 weeks.
3. severe cardiac arrhythmia
4. currently uncontrolled hyperthyroidism
5. active phaeocromocytoma
6. pregnancy, lactation or intended pregnancy in the
coming year
Taskila et al. BMC Public Health 2012, 12:182
http://www.biomedcentral.com/1471-2458/12/182
Page 3 of 137. a severe acute or chronic medical or psychiatric
condition or previously diagnosed clinically important
renal or hepatic disease, that may increase the risk asso-
ciated with study participation or may interfere with the
interpretation of study results and, in the judgment of
the investigator, would make the potential participant
inappropriate for entry into this study.
Withdrawal criteria
Given the established safety profile of NRT, we do not
expect any serious adverse events (SAE) and suspected
unexpected serious adverse reactions (SUSARs) due to
the medication. Nevertheless, pharmacists are required to
report in case of any SAE or SUSARs to Principal Investi-
gator. In the event of an SAE or SUSAR that is judged
either possibly, probably, or definitely related to NRT,
the prescription for NRT will be withdrawn and not re-
instituted in that person (Appendix 1).
Sample size
This is a pilot trial designed to test the processes, exam-
ine implementation issues, and reactions to the pro-
gramme of those involved. We estimated a sample size of
160 participants recruited in 10 pharmacies would be suf-
ficient to test the feasibility of the study. The outcomes
therefore include the percentage of pharmacists that
agree to participate, the percentage that are trained, the
percentage that actually recruit smokers into reduction
programmes. Our most important efficacy outcome
(because it is linked with unequivocal health benefits) is
smoking cessation. We will record the weekly recruit-
ment rate of patients into the reduction programmes and
into NHS stop smoking programmes, comparing the rate
of recruitment into stop smoking programmes for phar-
macists participating in the trial with those not doing so.
This will give evidence on whether smokers are being
diverted by reduction. For smokers in each type of pro-
gramme, we will record the number of contacts made,
the time of the pharmacist used in delivering the pro-
grammes, the amount of NRT used in each arm, the
number of people that try to quit, and the number of
people that attend the pharmacist for post-cessation sup-
port as a proportion of those that try to quit. We will
measure the fidelity to each programme by recording
some consultations and analysing their content against
the schedule of proposed content. We will record sus-
tained smoking reduction and abstinence, although the
trial is not powered to detect worthwhile differences in
the abstinence outcomes. Four week and six month absti-
nence rates will be measured following the Russell stan-
dard. We will record the proportion of people that
complete the webform/telephone follow up.
Any trial to test the role of behavioural support and
shorter versus standard length reduction programmes
w o u l dn e e dt ou s es i xm o n t hp r o l o n g e ds m o k i n ga b s t i -
nence as the outcome [11,12]. A sample of 160 partici-
pants is not large enough to provide definitive evidence of
efficacy with such an outcome because our systematic
review showed that standard length programmes lead to
about 7% of participants sustaining six month abstinence
[13]. However, we assume that shorter reduction pro-
grammes are about twice as effective, as suggested by the
Haustein trial. Our most important efficacy outcome here
is four week abstinence. Based on our systematic review,
we expect about 7% of participants who follow the stan-
dard length programme with behavioural support to sus-
tain abstinence for six months, which equates to about
21% achieving 4 weeks of abstinence, our main efficacy
outcome. Based on this, we get the following table, which
shows that this sample size will have 80% power to detect
ar a t er a t i oo f1 . 7o r9 0 %p o w e rt od e t e c tar a t er a t i oo f
1.8 (Table 1), lower than observed in Haustein.
The following are also considerations in the sample
size. If we take key process measures like attendance for
behavioural support sessio n sa s6 3 %( o b s e r v e di nt h e
review), with 80 smokers receiving behavioural support,
we could estimate this with +/-7% precision with 80%
confidence. Asking each pharmacy to treat 16 patients, 4
in each arm, will give a reasonable range of experiences
for them and us to evaluate the programmes.
Allocation to trial arms and treatment
Randomisation
Pharmacists will randomise smokers by sealed envelopes.
Block randomisation stratified by pharmacy will be used
with two blocks of 4 to ensure randomisation to each
arm in every pharmacy that recruits at least 4 partici-
pants. Although blocks of 4 could become predictable,
no pharmacist will recruit sufficient participants to dis-
cern the pattern. Telephonists conducting follow up will
be blind to treatment allocation but this is an open label
trial and participants and therapists will know which arm
they are in.
Behavioural intervention
This is a 2 × 2 randomised factorial design trial of beha-
vioural support versus no support and short versus stan-
dard length reduction programme (Figure 1). It is a pilot
study for a later definitive trial.
All participants will receive NRT and be randomised to
either behavioural support or no support and either stan-
dard length or short reduction; approximately 80 people
in each arm.
Behavioural support arms
Supported standard programme
The behavioural support schedule will follow that used
in the Nicorette industry trials, providing support and
m o n i t o r i n ga tb a s e l i n e ,2 ,6 ,1 0 ,1 6 ,2 2 ,2 8 ,a n d3 4
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Page 4 of 13weeks. The pharmacist giving support in a consulting
room will invite participants to set a treatment goal and
provide advice on how to reduce cigarettes using
unstructured or structured methods of smoking reduc-
tion. Unstructured smoking reduction means that parti-
cipants were not guided as to which cigarettes to
eliminate but are left to experiment themselves and
without a specific goal except 50% reduction by 6
weeks. Structured reduction means having specific
sequential goals for either reducing cigarettes per day or
reducing smoking periods. The cigarettes per day meth-
ods are either smoke-free periods (SFP) or lengthen the
inter-cigarette interval, i.e. the timer method [14,15].
Smoke-free periods concentrates on times when smok-
ing is allowed and when it is not, but the number of
cigarettes is not restricted. In the timer method the
number of cigarettes per day is restricted and also times
when smoking is allowed.
Supported short programme
Participants in the 4-week supported programme will be
given the same advice and help with reduction but this
will be provided on a different schedule. Participants will
be seen weekly for four weeks with the aim of reducing
smoking to achieve cessation by the end of four weeks. If
this fails, reducing to induce cessation at 8 weeks will be
the goal. Thereafter, consistent with the pragmatic nature
of this trial, participants in the short reduction arm will be
allowed to follow the standard reduction regime. Beha-
vioural support will be provided at baseline, weekly to 4
weeks, 6, 8, and 16 weeks i.e. the same number of visits
but on a different schedule.
No support arms
Participants in the no support arms will not be given
advice or support by the pharmacist. Instead they will
be given a leaflet that describes the reduction pro-
grammes (unstructured, cigarettes per day, or smoking
periods) and which gives brief advice on using one or
more of these approaches, and encourages use of NRT
to support this. Participants will be advised to reduce on
a schedule that follows the standard programme, if ran-
domised to that arm, or the short programme, if rando-
mised to that arm. The leaflet will advise participants to
return to the pharmacy for more NRT to support reduc-
tion as needed. This will be dispensed on NHS prescrip-
tion (following the primary care trust’sp a t i e n tg r o u p
direction). The outcomes will be monitored without per-
sonal visits to avoid the possibility that these are contri-
buting to adherence to the programme.
Transferring to the cessation programme
The aim of the reduction programme is to help people
reduce and pharmacists will be encouraged not to pressure
people to stop smoking, while explaining that proven
health benefits derive from smoking cessation rather than
reduction. However, most people who want to reduce
smoking want to do so as a way of stopping [16,17],
though rarely with a predetermined timetable. It is for the
therapist and the patient to determine whether and when
a person is transferred to the cessation programme. Poin-
ters towards possible cessation are:
￿ Increased confidence that the patient can control
her/his smoking.
￿ Cigarette consumption has fallen to five per day or
fewer, or the person is going most of the day without
smoking.
Participants in the No-support arms will be asked about
their quitting attempt when they return to the pharmacy
f o rm o r eN R T .Ak e yp r i n c i p l eo ft h ew h o l er e d u c t i o n
approach is that failed quit attempts do not lead to an end
of the programme. If a person moves to cessation and the
quit attempts fails, they can resume the reduction pro-
gramme and continue to control their smoking until they
are ready to stop again.
Length of study
We plan to recruit 10 pharmacies. If they each recruit
four participants per month, they will recruit their quota
of 16 in 4 months. We plan two waves of recruitment,
with final follow up of that cohort one year after the end
of recruitment. The second wave of pharmacies will
Table 1 Efficacy of shorter reduction programmes versus standard length
80% power 90% power
Base quit proportion RR Quit proportion in intervention N in each arm N in each arm
0.21 1.7 0.357 146 195
0.21 1.8 0.378 114 152
0.21 1.9 0.399 91 122
Behavioural support (N80) No behavioural support (N80)
Short (N40) Standard (N40) Short (N 40) Standard (N40)
Figure 1 Randomised factorial design trial (2 × 2) of
behavioural support versus no support on smoking reduction.
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Page 5 of 13begin recruiting approximately six months after the first
wave of recruitment. In total the duration will be 30
months.
The end of the trial is defined as last contact with any
trial participant.
Trial Outcomes
This is a pilot trial designed to test the processes, examine
implementation issues, and reactions to the programme of
those involved i.e. whether pharmacists can be trained to
implement the reduction programme, how well they do
so, and how this is received by smokers and by pharma-
cists. These processes will be measured by:
￿ The percentage of pharmacists that agree to partici-
pate and the percentage that are trained and pass an
assessment of competence.
￿ The monthly recruitment rate of patients into reduc-
tion programmes and into NHS stop smoking pro-
grammes, comparing the rate of recruitment into stop
smoking programmes for pharmacists participating in
the trial with those not doing so.
￿ Recording of some consultations and analysing their
content against the schedule of proposed content.
￿ The proportion of people that would recommend
the smoking reduction programme to another smoker
and their views on the way that it ran, taken from the
12 month evaluation questionnaire.
We will also examine whether behavioural support is
more effective than no support and will investigate
whether shorter reduction programmes are more effective
than standard length reduction programmes. This will be
achieved by measuring self-reported sustained smoking
reduction and abstinence. Smoking cessation outcomes
will be measured from the time of quitting and we will
measure 4 week and 6 month prolonged abstinence fol-
lowing the Russell standard, i.e. by intention to treat and
biochemically confirmed [12]. Thus abstinence will be
defined as allowing a two week grace period after quit day
in which smoking lapses do not count against abstinence
and from day 15 onwards, no more than five cigarettes
have been smoked. This will be verified by a CO < 10
ppm. Smoking reduction will be assessed by the propor-
tion of people that reduce their consumption to < 50% of
baseline value, the mean cigarette consumption at the end
of the trial.
As this is a preliminary trial, we will record data to
allow us to assess whether the processes of the trial need
improvement prior to a definitive trial. We will also
examine data on adverse events and drop outs from the
programme (Appendix 1).
Follow up procedures
We propose testing the feasibility of using a follow up
method that is unlikely to be perceived by participants
as providing them with behavioural support or enhance
motivation to adhere. This will be by email/Webform
emailed monthly for the 12 months of a participant’s
involvement in the trial. Monthly follow up will ensure
that we can assess whether smokers have started their
period of abstinence and schedule verification visits,
based on a process outlined for trials of this kind [18].
Web follow up has achieved > 90% follow up in a pre-
vious trial [19]. Based on our experience of trials in
smokers’ clinics, most patients have email addresses and
these are useful for follow up. Text reminders will be
sent to participants registered for email follow up not
responding to the email. For those not using a computer
regularly, phone follow up by telephonists will be used
so that the pharmacist/therapist is not conducting fol-
low up.
Sustained smoking reduction will be measured as self-
reported daily cigarette consumption at 12 month follow
up, with a reduction being counted as self-reported con-
sumption lower than at baseline. Sustained reduction will
be counted as achieved if during the last four months (i.e.
reports at month 9-12) of follow up, a person is smoking
less at every follow up occasion than at baseline, measured
by self-report. If a monthly report is missing, a person will
be counted as having achieved sustained reduction if all
other reports show this is the case and the last report is
not missing. If two reports are missing, a person will be
counted as not having achieved sustained reduction. Mean
cigarettes per day at the end of follow up will be calculated
from the last follow up only. If cigarettes per day is miss-
ing, then this will be replaced by baseline cigarettes per
day, but in sensitivity analysis, we will use last observation
carried forward.
Participants who have maintained abstinence for 4
weeks will be asked to attend the pharmacy for carbon
monoxide (CO) verification if they are in the self-help
arm or if they are in the supported arm but are not due
for or have ceased to attend visits. Those who have main-
tained abstinence for 6 months (defined in the same way
with a grace period and no more than five cigarettes
smoked) will be asked to return for CO verification in
the same way. Participants attending the pharmacy for a
non-therapeutic reason i.e. to attend for abstinence verifi-
cation will be paid £20 to compensate them for their time
and any travel costs incurred.
Data analyses
Statistics
We will calculate descriptive statistics for the outcome
measures comparing these by arm where it is sensible to
do so. Risk differences with 95% confidence intervals
will be calculated for binary outcomes such as cessation,
and for continuous outcomes, such as reduction in
cigarettes per day, we will calculate difference in means
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Page 6 of 13or difference in change in means. For the cessation and
reduction outcomes, we will conduct an intention-to-
treat analysis, where all randomized subjects will be
included in the denominator. We will also conduct sen-
sitivity analyses with different assumptions for missing
data.
T h ed a t aw i l lb ea n a l y s e db yam u l t i l e v e lm o d e lb y
examining diversion of smokers from cessation into
reduction programmes by comparing uptake of cessation
in the pharmacies prior to and during the reduction pro-
grammes with pharmacies providing a similar throughput
of patients for cessation support but not selected to pro-
vide reduction programmes.
Health economic analyses are not required because
extensive modelling of different formats of reduction pro-
grammes showed that each of these programmes are cost-
effective by NHS standards and this was robust to changes
in assumptions [3]. However, we will utilise our existing
models of the cost-effectiveness of the programme by
updating the estimates used in modelling by including
these estimates derived from a naturalistic setting. The
updated estimates will be used to set the sample size for a
definitive trial.
Qualitative process evaluation
Qualitative research can contribute depth of understand-
ing on why programmes achieve the effects that they do
[20,21] and we will use semi-structured interviews with
pharmacists and trial participants to determine key factors
in relation to initial engagement, ongoing participation
and overall response to the programme and the trial. We
will purposively selected 4 to 6 pharmacists, some of
whom recruited none or few participants and some who
recruited many. Semi-structured interviews will investigate
factors that influence pharmacist recruitment to the pro-
gramme and clinical trial, response to training issues, their
experiences of implementing the reduction programme
and recruiting. The interviews will cover the factors that
hindered or facilitated pharmacists’ ability to recruit parti-
cipants and their perceptions of smokers’ reactions to
behavioural support and medication provided within the
programmes. Delivery of the overall programme and beha-
vioural support will be explored including how support
delivery is organised within the pharmacy and by whom.
Pharmacists will be asked about their understanding of
tobacco addiction and its treatment and about tobacco
control in general and where smoking reduction fits in,
because there is evidence from studies among GPs that
these broader attitudes affect the clinical treatments doc-
tors give their patients.
Trial participants will be approached by the research
fellow who will select some who have used each of the
permutations of support/no support and short/standard
reduction programmes. Participants who drop out,
reduced and quit smoking, reduced only, or achieved no
success with the programmes will be approached for
interview. We expect to enrol about 2 people per permu-
tation i.e. about 26 in total. The interviewer will enquire
about their motivation for using the programme, their
experience of it, and what if any changes occurred to
their smoking and why they thought they occurred.
Responses to trial follow-up methods will also be
explored.
The interviews will be audio-recorded and transcribed
with respondents’ permission. Interviews will be con-
ducted by the research fellow at a time and location con-
venient to respondents and trial participants will be
offered financial compensation of £20 for their time to
acknowledge their contribution to the study. The inter-
views will be systematically read and interpreted, compar-
ing key features of emergent findings and concepts to
minimise bias in interpreting data [22,23]. We will use
open coding to identify emergent themes, and categories
within these. We will interweave data collection and analy-
sis, conducting later interviews after initial data analysis to
provide insights for refining each theme and category.
Trial Medication
Participants are encouraged to use both a nicotine patch
and a short-acting (acute) form of NRT and those who are
eligible to pay a prescription charge on the NHS (£7.20)
will have to do so for each item dispensed. Combination
patch plus acute NRT is becoming a standard dosing regi-
men for cessation treatment [24], with manufacturers now
packaging combined products. This is because of superior
efficacy in enhancing cessation of combination over single
form NRT [24]. There are fewer trials of NRT in smoking
reduction, too few to assess the relative efficacy of the dif-
ferent NRT preparations [2], and no trials of combination
NRT versus single form NRT. Therefore the dose regimen
is based upon limited trial evidence and extension of the
evidence from its use in cessation (reduction to zero cigar-
ettes). A systematic review of placebo controlled short-
term trials of nicotine patch and acute NRT show that
both reduce daily cigarette consumption in people who
are not trying to reduce their smoking and people who are
[25]. Both patch and acute NRT appear equally effective in
assessing reduction. One long-term trial allowed people
free choice between patch, gum, and inhaler and found
t h a tg u mp r o d u c e dt h eg r e a t e r reduction of cigarettes
than patch or inhaler [26]. The rationale for patch use is
that smokers find regular use of the patch very easy, with
typically very high levels of adherence [27], while acute
NRT dosing is often sub-optimal [28]. However, acute
NRT provides a direct behavioural replacement of cigar-
ettes (such as ‘have a piece of gum when you would ordi-
narily smoke’) and this appears important in smoking
reduction [29]. This population have relatively low interest
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for up to a year, so a combination approach seems most
likely to produce optimal adherence to regimen and opti-
mal efficacy.
T h e r ei sn of o o l p r o o fw a yt og i v eap e r s o ne x a c t l yt h e
right dose of nicotine. However, serious problems from
too much nicotine replacement are uncommon in smo-
kers. All smokers have had episodes of rapid smoking and
can easily identify symptoms resulting from too much
nicotine and can cut back. Furthermore, nicotine replace-
ment, particularly in the form of patches, delivers nicotine
in a very slow form. Experience of using high dose nico-
tine patches (up to 63 mg daily) shows that side-effects
from ‘overdose’ are unusual when nicotine is given slowly
to smokers [25]. On the other hand, there is good evidence
that the smoking reduction without NRT or with an
inadequate dose of NRT is much less effective [2]. Bearing
these considerations in mind, we propose the following
dosing algorithm.
Initial patch dose
￿ < 10 cigs/day - 7 mg/24 hour patch or 5 mg/16 hour
patch
￿ 10-19 cigs/day - 14 mg/24 hour patch or 10 mg/16
hour patch
￿ 20+ cigs/day - 21 mg/24 hour patch or 15 mg/16
hour patch
This dosing guideline should be modified according to
exhaled carbon monoxide (CO) reading and patient
preference.
￿ < 10 ppm - 7 mg/24 hour patch or 5 mg/16 hour
patch
￿ 10-19 ppm - 14 mg/24 hour patch or 10 mg/16 hour
patch
￿ ≥20 ppm - 21 mg/24 hour patch or 15 mg/16 hour
patch
The patch dose from cigarettes per day will be esti-
mated by exhaled CO. If there is a conflict, the pharma-
cist should generally use the higher suggested dose.
Pharmacists are emphasised that CO levels are typically
lower in the morning rising steadily through the day;
therefore the dosing guidelines are only approximate
Participants will be advised to remove the patch at night
and replace with a new patch each morning i.e. use under
16 hours only, even if the product is a 24 hour patch. One
of the most frequent side-effects of patch is vivid dreams
or insomnia and using over 16 hours prevents this, with
no decrement in efficacy [24]. Reducing adverse reactions
is a key aim of treatment that might last for nine months.
Initial short-acting NRT dose
Participants can have free choice of nicotine inhalator, 2
mg gum, 2 mg sublingual tablets, 2 mg lozenges, or
nasal spray.
￿ For gum, lozenge, or sublingual tablets, participants
should replace each missed cigarette with one of their
chosen product.
￿ For nasal spray, participants should take one spray in
each nostril to replace each missed cigarette.
￿ For inhalator, patients should puff as often as is
needed. As a rough guide, 40-80 puffs on the inhalator
replace one cigarette.
Participants will be strongly encouraged to use both a
patch and a short-acting form of NRT concurrently. How-
ever, participation in the study depends upon willingness
to use NRT in general, so individuals prepared to use only
one form of NRT will be allowed to participate. Partici-
pants will choose the preferred product together with
pharmacists. Participants are allowed to change their NRT
at anytime during the trial.
Dose alteration procedure
Overdose of nicotine is unlikely in clinical practice using
the above products. There is still a common perception
that it is inadvisable to use NRT and smoke, although
the data suggest that this is not true [2,27]. This belief
is reinforced by the old labelling that advised people not
to smoke while using NRT. The Medicines and Health-
care Regulatory Authority (MRHA) has removed this
from all products, but the perception is slower to
change, so we will advise pharmacists to reassure
patients.
Although nausea or indigestion can be symptoms of
overdose, they are common adverse events to oral or nasal
NRT and are an unreliable guide to overdose. Likewise,
some symptoms such as agitation or restlessness are both
symptoms of nicotine withdrawal suggesting under-dosing
and of overdose. Pharmacists will therefore be advised to
look for definite symptoms of:
￿ Muscular twitching
￿ Dizziness
￿ Confusion
￿ Rapid pounding heart
￿ High blood pressure
￿ Vomiting
￿ Weakness
Assuming overdose symptoms are not present, then the
option for dose alteration will be either to continue with
the present patch dose, or to increase the patch dose to
the next step i.e. from 7 mg to 14 mg or 14 mg to 21 mg
o rf r o m5m gt o1 0m go r1 0m gt o1 5m go r1 5m gt o
25 mg. Criteria for suggesting an increased dose of patch
are as follows
￿ The patient wants to reduce smoking further
￿ The patient is finding smoking reduction difficult
because s/he is feeling irritable, edgy, and urges to
smoke in periods when smoking is ‘not allowed’ by the
programme they are following.
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dose for all practical purposes because practical consid-
erations (such as the need to eat), or local irritation from
the products, and the sensation of having used too much
nicotine within a short time of using the product, natu-
rally limit the dose consumed. The patient will be advised
to replace each additional missed cigarette with a short-
acting form of NRT as described in the initial dosing.
Should a person find that going without cigarettes is diffi-
cult; the dose of short-acting NRT should be increased in
the following way:
￿ For gum or lozenge, increase the dose from 2 mg
lozenge to 4 mg lozenge.
￿ For sublingual tablets, participants should use two
microtabs at a time.
￿ For nasal spray, participants should administer two
sprays in each nostril to replace each missed cigarette.
￿ For inhalator, patients should puff as often as is
needed.
￿ Modification of medication regime
Participants who have problems with insomnia or diffi-
culties with vivid dreams will use the patch for 16 hours
daily, not 24 hours. Participants who have skin reactions
to the patch that are not controlled by switching prepara-
tions, emollient and hydrocortisone cream will switch to
short-acting NRT only.
￿ Participants who become pregnant may have their
dose adjusted in line with NICE guidance(8) and in
accord with the wishes of the participant.
￿ Participants who show symptoms of overdose will
have the dose reduced.
￿ Participants who give up on their reduction attempt
will cease using NRT.
￿ Participants who experience adverse reactions or
adverse events will stop using NRT products, definitively
or temporarily, when deemed necessary by the study
physician
￿ Participants who stop the treatment early will not be
replaced, and they will be followed-up like the other
participants.
Pharmacists are advised to apply same guidelines for
patients who come to them with any above issues if
they are in the arm of the study which does not give
behavioural support.
Concomitant medication
All medications will be permitted for use concurrently,
except those that are proven to help smoking cessation
(bupropion, nortriptyline, mecamylamine, reserpine, vare-
nicline), or medications that are unlicensed and for which
no interaction data with NRT are available. The NRT itself
is aimed at the relief of symptoms of nicotine withdrawal.
Should adverse skin reactions occur with the use of the
patch, advice will be given on the use of over the counter
emollients and 1% hydrocortisone cream, as is standard.
Data on all concomitant medication will be recorded.
Discussion
The findings from the proposed trial are timely and
highly relevant in public health as there is a recognized
need to support smokers who feel unable to quit to
reduce their smoking instead. The Department of
Health (DH) proposed a new tobacco control strategy
that envisaged ‘tailored quit plans’ meaning smoking
reduction as an intermediate goal without necessarily
committing to abstinence. Although the DH has com-
mitted to harm reduction, there is no trial showing that
allowing reduction alongside cessation leads to greater
health benefits than offering abrupt cessation only. This
is a pilot study to assess the feasibility of offering smok-
ing reduction programme within pharmacies that offer
naturalistic setting to show population benefit from
these programmes. In addition, findings from this trial
will inform the development of evidence-based treat-
ment for smokers who want to reduce and best
approaches to engage reluctant quitters onto the
programme.
Procedures for handling the data
Data Management
The trial will run as part of the portfolio of trials in the
Primary Care Clinical Research and Trials Unit
(PCCRTU), an NIHR recognised trials unit in Primary
Care Clinical Sciences at the University of Birmingham.
The data management will be run in accord with the
standard operating procedures (SOPs), which are fully
compliant with the Data Protection Act and Interna-
tional Conference on Harmonisation (ICH) and Good
Clinical Practice (GCP). The source documents for the
trial will be the case report forms (CRFs) which will be
stored in the pharmacies in a locked cabinet in a locked
office. The trial database will be securely held and main-
tained by the PCCRTU. Data cleaning will take place by
a series of logical checks on the electronic data. (For
example, a person cannot be recorded as prolonged
abstinent smoker at 6 months if they were not in such a
state at 8 weeks). Discrepant records will be checked
with the source documents and the database amended if
necessary. On completion of the trial and data checking,
the CRFs will be transferred to Modern Records, a
secure archiving facility at the University of Birming-
ham, where they will be held for 15 years and then
destroyed. The database will be anonymised and a
secure compact disc containing the link between identi-
fication number and patient identifiable information will
be stored in modern records.
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Data will be kept in accordance with the Data Protection
Act and the trial registered with the Data Protection Act
website at the University of Birmingham. The SOPs of the
trials unit will be followed, which are designed to protect
patient confidentiality. Patient identifiable data will be
shared only within the clinical team on a need-to-know
basis to provide clinical care and ensure good and appro-
priate follow up. Patient identifiable data will also be
shared with the GP and approved auditors from the
Research Ethics committee (REC), NHS Research and
Development, or the MHRA will also be able to see
patient identifiable information. Otherwise, confidentiality
will be maintained and no one outside the trial team will
have access to either the CRFs or the database. No data
relating to individuals will be identified in publications.
Ethical approval
The trial will be conducted in compliance with the princi-
ples of the Declaration of Helsinki (1996), the principles of
ICH-GCP and run in accord with EU Clinical Trials
Directive and all of the applicable regulatory requirements.
The study protocol and other documentation have been
approved by the Birmingham East, North and Solihull
Research Ethics Committee, 14
th of June 2010 (REC refer-
ence number: 10/H1206/22) and amendment on 21
November 2011 (Amendment number: AM01). Any sub-
sequent protocol amendments will be submitted to the
REC for approval and the other bodies if necessary. We
will comply with ICH-GCP Guidelines over the reporting
of adverse events, serious adverse events, and suspected
serious adverse reactions (SUSARS). In addition we will
provide the REC with progress reports as well as a copy of
the Final Study Report.
Dissemination of the results
The trial results will be written up for submission to peer
reviewed scientific journals and presented in national and
international conferences. No data relating to individuals
will be identified.
Funding
The study is funded by the award of a grant from the
Prevention Research Advisory Board of the National
Prevention Research Initiative (NPRI)
Appendix 1 Adverse Event Reporting
Definitions
B.1. Adverse event
An AE is any untoward medical occurrence in a clinical
investigation participant administered a product or med-
ical device; the event need not necessarily have a causal
relationship with the treatment or usage. Examples of
AEs include but are not limited to:
￿ abnormal test findings,
￿ clinically significant symptoms and signs,
￿ changes in physical examination findings,
￿ hypersensitivity, and
￿ progression/worsening of underlying disease.
Additionally, they may include the signs or symptoms
resulting from:
￿ drug overdose,
￿ drug withdrawal,
￿ drug abuse,
￿ drug misuse,
￿ drug interactions,
￿ drug dependency,
￿ exposure in utero.
Failure of expected pharmacological action or thera-
peutic benefit alone (i.e. lack of efficacy) is not necessa-
rily an AE.
B.2. Definition of serious adverse event
A serious adverse event or serious adverse drug reaction
is any untoward medical occurrence at any dose that:
results in death, is life-threatening (immediate risk of
death), requires inpatient hospitalisation or prolongation
of existing hospitalisation, results in persistent or signifi-
cant disability/incapacity, and/or results in congenital
anomaly/birth defect. An important medical event may
not be immediately life-threatening and/or result in
death or hospitalisation. However, if it is determined that
the event may jeopardize the participant and may require
intervention to prevent one of the other outcomes listed
in the definition above, the important medical event
should be reported as serious. Examples of such events
are intensive treatment in an accident and emergency
department or at home for bronchospasm; blood dyscra-
sias or convulsions that do not result in hospitalisation;
or development of drug dependency or drug abuse. Ser-
ious adverse events will be those that occur during the
period of medication use or within 7 or more days of
ceasing medication use.
B.3. Definition of suspected serious adverse reaction (SSAR)
Means an adverse reaction that is classed as serious and
which is consistent with the information about the med-
icinal product in question set out (in the case of a
licensed product, in the summary of product character-
istics for that product.)
B.4. Definition of suspected unexpected serious adverse
reaction (SUSAR)
Means an adverse reaction that is classed as serious and
which is not consistent with the information about the
medicinal product in question set out (in the case of a
licensed product, in the summary of product character-
istics for that product)
B.5. Monitoring and reporting adverse events
NRT is a well tried and tested medication and there are
minor common and well known side-effects that it will
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NRT almost universally causes burning in the mouth
that most people find initially unpleasant but become
used to in due time. Where adverse events are listed in
SPC as expected and are classified as mild, pharmacists
w i l ln o tb er e q u i r e dt or e c o r dt h e s eo nt h ea d v e r s e
event form.
For all other adverse events (i.e. moderate or severe or
possibly serious), the investigator will pursue and obtain
information adequate both to determine the outcome of
the adverse event and to assess whether it meets the cri-
teria for classification as a serious adverse event requiring
immediate notification to the sponsor, the NHS R&D
office, and the research ethics committee. The investiga-
tor will assess causality. For adverse events follow-up by
the investigator is required until the event or its sequela
resolve or stabilise.
B.6. Severity Assessment
The treating clinician or investigator will use the adjec-
tives mild, moderate, or severe to describe the maximum
intensity of the adverse event. For purposes of consis-
tency, these intensity grades are defined as follows:
￿ Mild- Does not interfere with participant’su s u a l
function.
￿ Moderate- Interferes to some extent with partici-
pant’s usual function.
￿ Severe- Interferes significantly with participant’s
usual function.
Note the distinction between the severity and the ser-
iousness of an adverse event. A severe event is not neces-
sarily a serious event. For example, a headache may be
severe (interferes significantly with participant’su s u a l
function) but would not be classified as serious unless it
met one of the criteria for serious adverse events, listed
above.
B.7. Exposure In Utero
The license for NRT does not exclude use in pregnancy
and NICE guidelines allow such use. We will exclude
pregnant or breast feeding women because the dose
a n df o r m a to fN R Ta d v i s e df o rp r e g n a n tw o m e ni sd i f -
ferent from that used in our protocol. Consequently,
w ew i l la d j u s tt h ed o s eo fN R Ts h o u l daw o m a n
become pregnant during treatment. As NRT use in
pregnancy is routine in NHS practice, we will not fol-
low up such women to determine the outcome of preg-
nancy in such cases.
B.8. Causality Assessment
The pharmacist’s or investigator’s assessment of causality
must be provided for all adverse events (serious and non-
serious). An investigator’s causality assessment is the
determination of whether there exists a reasonable possibi-
lity that the investigational product caused or contributed
to an adverse event. If the investigator’s final determina-
tion of causality is unknown and the investigator does not
know whether or not investigational product caused the
event, then the event will be handled as “related to investi-
gational product” for reporting purposes. If the investiga-
tor’s causality assessment is “unknown but not related to
investigational product”, this should be clearly documen-
ted in the CRF. In addition, if the investigator determines
a serious adverse event is associated with trial procedures,
the investigator must record this causal relationship, as
appropriate, and report such an assessment in accordance
with the serious adverse event reporting requirements, if
applicable.
B.9. Evaluation of AEs for causality
￿ Not Related. Onset of the event as relative to adminis-
tration of the product, is not reasonable; or, another
cause itself can explain the occurrence of the event
￿ Unlikely to be related. Onset of the event as relative
to administration of the product is possible but another
cause itself can explain the occurrence of the event or
there are no reasonable grounds for suspecting that the
product could have caused the event.
￿ Possibly related. Onset of the event as relative to
administration of the product is reasonable; however the
event could have been due to another, equally likely,
cause
￿ Probably related. Onset of the event as relative to
administration of the product is reasonable and is more
likely explained by the drug than by any other cause.
￿ Definitely related. Onset of the event as relative to
administration of the product is reasonable and there is
no other cause to explain the event; or a re-challenge (if
feasible) is positive.
AE is classified as “not related” or “unlikely to be
related” in case the patient has stopped using NRT
seven days or longer at occurrence of the event.
The pharmacists/clinicians’ responsibilities and pro-
cesses for evaluating AEs
The participant will be encouraged to report AEs to the
pharmacist, who will manage these in the normal manner
for reported AEs. The pharmacist completes a form
called: “Undiagnosed health problem or hospitalisation/
death/disability log” in the CRF. In the case of SUSARs
or SAEs, the pharmacist will report to the PI or other
member of the investigating team within 24 hours of
becoming aware of such a possible occurrence. In case
the research team becomes aware of the occurrence first,
the Principal Investigator will inform the pharmacist and
fill in the log in the online CRF. It is pharmacist’s respon-
sibility to ensure that both versions of the CRF log
(online and paper version) are accurate.
B.10. The CI/PI’s responsibilities and processes for
evaluating AEs
Each AE reported to the PI will be evaluated for serious-
ness, causality, expectedness and severity. The responsi-
bility for this will lie with Dr Paul Aveyard, the PI.
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AE has a possible causal relationship to the trial inter-
vention, and/or is unexpected. In this case Dr Aveyard
will report the event to the sponsor as soon as being
made aware of the event. An initial verbal report can be
made but will be followed promptly with a detailed writ-
t e nr e p o r to nt h et r i a lS A Ef o r mT h ec o p yo ft h ef o r m
will be filed in the trial master file.
Timeframes in which the Sponsor will submit expe-
dited reports to the Research Ethics Committee (REC)
and to the Medicines and Healthcare Products Regula-
tory Agency (MHRA)
B.10.1. Fatal/life threatening SUSARs The sponsor
will inform the REC of the above as soon as possible,
but no later than 7 calendar days after he has first
knowledge of the minimum criteria for expedited
reporting.
B.10.2. Non-fatal and non-life threatening SUSARs
The sponsor will report all other SUSARs and safety
i s s u e st oO X R E Ca ss o o na sp o s s i b l eb u tn ol a t e rt h a n
15 calendar days after he has first knowledge of the
minimum criteria for expedited reporting.
B.10.3. Reporting other safety issues A letter entitled
Safety Report will be sent to the REC where other safety
issues also qualify for expedited reporting by the spon-
sor. The Co-ordinator of the main REC will acknowl-
edge receipt of safety reports within 30 days.
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